Mutlu Hasan, Coşkun Hasan Şenol
Department of Medical Oncology, Akdeniz University, Antalya, Turkey
Department of Medical Oncology, Akdeniz University, Antalya, Turkey.
J Oncol Pharm Pract. 2015 Dec;21(6):468-70. doi: 10.1177/1078155214538686. Epub 2014 Jun 5.
Trastuzumab is one of the most important agents that target human epidermal growth factor receptor 2, but its cardiotoxic effect limits to use it. The mechanism of cardiac dysfunction-related trastuzumab is still unclear. In literature, there is no definite information about the cumulative dose of trastuzumab for cardiotoxicity. In presented case, we reported a breast cancer patient who has been receiving long-term trastuzumab. We have not found any cardiac problems for duration of over four years. According to our case and literature review, we may say that trastuzumab is safely used with periodically echocardiographic control in patients with breast cancer.
曲妥珠单抗是靶向人表皮生长因子受体2的最重要药物之一，但其心脏毒性作用限制了它的使用。与曲妥珠单抗相关的心脏功能障碍机制仍不清楚。在文献中，关于曲妥珠单抗心脏毒性的累积剂量没有确切信息。在本病例中，我们报告了一名长期接受曲妥珠单抗治疗的乳腺癌患者。在四年多的时间里，我们未发现任何心脏问题。根据我们的病例及文献回顾，我们可以说，在乳腺癌患者中，定期进行超声心动图检查的情况下，曲妥珠单抗可安全使用。
